Press Room

The one-house budget proposals revealed a clear divide in the Legislature’s approach to the equitable treatment of disease. The New York State Senate flatly rejected the governor’s proposal to roll back Medicaid coverage criteria for biomarker testing, heeding the calls of cancer survivors, patient advocates and public health organizations, like the American Cancer Society Cancer Action Network (ACS CAN). The Assembly took a more mixed approach accepting parts of the Governor’s proposed language while rejecting others.  

Earlier today, legislation was introduced in the New Jersey Assembly as a companion to Senate Bill 773, proposing to increase the state’s investment in the New Jersey Commission on Cancer Research (NJCCR). Assembly Bill 4579 would establish a dedicated, non-lapsing investment in the amount of $10 million, utilizing a greater proportion of the state tobacco tax revenue to do so. With bills now moving in both chambers, survivors and advocates with the American Cancer Society Cancer Action Network (ACS CAN) are encouraged by the growing momentum to expand support for cancer research and accelerate lifesaving innovations.

The American Cancer Society Cancer Action Network (ACS CAN) is expressing strong disappointment with the final passage of HB 337, Nicotine Product Tax Amendments.

The Oklahoma House today ignored the clear will of its constituents and advanced House Joint Resolutions 1050 and 1077 out of committee, putting at risk one of the state’s most effective public health initiatives. These proposals would significantly alter and undermine the voter-established Oklahoma Tobacco Settlement Endowment Trust (TSET).